| |  Online-Ressource |
|---|
| Verfasst von: | Kasper, Bernd [VerfasserIn]  |
|---|
| | Scharrenbroich, Peter-Ingo [VerfasserIn] |
|---|
| | Schmitt, Thomas [VerfasserIn] |
|---|
| | Wuchter, Patrick [VerfasserIn] |
|---|
| | Dietrich, Sascha [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| | Egerer, Gerlinde [VerfasserIn] |
|---|
| Titel: | Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas |
|---|
| Titelzusatz: | prospective, single-institutional phase II study |
|---|
| Verf.angabe: | B. Kasper, I. Scharrenbroich, T. Schmitt, P. Wuchter, S. Dietrich, A.D. Ho and G. Egerer |
|---|
| E-Jahr: | 2010 |
|---|
| Jahr: | 23 November 2009 |
|---|
| Umfang: | 5 S. |
|---|
| Fussnoten: | Gesehen am 02.03.2023 |
|---|
| Titel Quelle: | Enthalten in: Bone marrow transplantation |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2010 |
|---|
| Band/Heft Quelle: | 45(2010), 7, Seite 1234-1238 |
|---|
| ISSN Quelle: | 1476-5365 |
|---|
| Abstract: | Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, single-institutional phase II study that enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease. After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n=9); all other patients continued chemotherapy for two more cycles. After standard chemotherapy, PR (n=10), stable disease (SD, n=6) and progressive disease (PD, n=14) were attained for the evaluable patients. Twenty-nine patients died and five are alive with the disease. Median PFS was 11.6 months (range 8-15) for patients treated with high-dose chemotherapy (n=9) vs 5.6 months (range 0-19) for patients treated with standard chemotherapy. Median OS was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. The subgroup of patients treated with high-dose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational. |
|---|
| DOI: | doi:10.1038/bmt.2009.333 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1038/bmt.2009.333 |
|---|
| | Volltext: https://www.nature.com/articles/bmt2009333 |
|---|
| | DOI: https://doi.org/10.1038/bmt.2009.333 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Cell Biology |
|---|
| | general |
|---|
| | Hematology |
|---|
| | Internal Medicine |
|---|
| | Medicine/Public Health |
|---|
| | Public Health |
|---|
| | Stem Cells |
|---|
| K10plus-PPN: | 1837965293 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas / Kasper, Bernd [VerfasserIn]; 23 November 2009 (Online-Ressource)
